CN109486783A - A kind of ω being catalyzed sitafloxacin five-membered ring intermediate-transaminase mutant - Google Patents
A kind of ω being catalyzed sitafloxacin five-membered ring intermediate-transaminase mutant Download PDFInfo
- Publication number
- CN109486783A CN109486783A CN201811449183.XA CN201811449183A CN109486783A CN 109486783 A CN109486783 A CN 109486783A CN 201811449183 A CN201811449183 A CN 201811449183A CN 109486783 A CN109486783 A CN 109486783A
- Authority
- CN
- China
- Prior art keywords
- mutant
- transaminase
- amino acid
- glu
- sitafloxacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses ω-transaminase mutant that one kind can be catalyzed sitafloxacin five-membered ring intermediate, belong to genetic engineering and technical field of enzyme engineering.The present invention is by carrying out rite-directed mutagenesis to the higher amino acid of Factor B in ω-transaminase crystal structure, the Y at 32 position of ω-transaminase is mutated into W, Y at 159 positions is mutated into F, I at 215 positions is mutated into M, T at 252 positions is mutated into A, has obtained a kind of ω-transaminase mutant that can be catalyzed sitafloxacin five-membered ring key intermediate.Mutant Y32W/Y159F/I215M/T252A catalytic efficiency Kcat/Km of the present invention is 0.49min‑1·mM‑1When being catalyzed (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine generation 5-benzyl-5-azaspiro [2.4] heptan-7-one, 5-benzyl-5-azaspiro [2.4] the heptan-7-one maximum conversion rate of mutant is 77.14%.The mutant that the present invention obtains is suitable for the application of industrially chiral synthesis sitafloxacin five-membered ring key intermediate.
Description
Technical field
The present invention relates to ω-transaminase mutant that one kind can be catalyzed sitafloxacin five-membered ring intermediate, belong to gene work
Journey and technical field of enzyme engineering.
Background technique
Broad spectrum quinolone class antimicrobial --- the sitafloxacin of Japanese first pharmacy Sankyo Co., Ltd exploitation in 2008
(Sitafloxacin Hydrate) has good bactericidal effect to many common bacterial strains of resistance to fluoroquinolones of clinic, for treating
Serious Difficult infection disease.Compared with other quinolone medicines, the Daily Drug Cost of this product is low, therapeutic effect and safety
It is good.But the key technical problems in its synthesis technology are asymmetric syntheses sitafloxacin five-membered ring key intermediates.The technique
Technical restriction that is unstable, at high cost, being difficult to amplify production seriously limits the production of sitafloxacin.Compared to chiral amine medicine
The chemical synthesis process of object, the enzyme asymmetry catalysis of biological synthesis method is with its Substratspezifitaet, stereoselectivity is strong, reaction
The advantages such as mild condition, environmental-friendly attract attention.Therefore the biological synthesis method of enzyme asymmetry catalysis with more research and is answered
With value.
Transaminase (aminotransferase, transaminase) belongs to transferase, commonly used in catalytic amino by
Amino group donor compound is transferred to amino acceptor compound.According to the difference of different variable regions, by separate sources reported in the literature
The protein sequence of transaminase be compared and clustering, superposition and iteration comparison further according to hydrophilic site, Wo Menke
Transaminase is divided into 4 classes.Wherein ω-transaminase belongs to the second subtribe, is usually used in preparing Chiral Amine and unnatural amino acid, such as
Beta-amino acids.Because the big pocket bond area of ω-transaminase is than aspartate transaminase (AspATs) and aromatic series transaminase
(AroATs) slightly larger, so it can combine substrate more biggish than natural amino acid volume.Transaminase-catalyzed reaction master
There are asymmetric syntheses and Kinetic Resolution, using Enzyme catalyzed synthesis chirality aminated compounds, can not only greatly improve production
Rate can also avoid the waste of raw material, the higher chiral aminated compounds of a large amount of optical purity is made.ω-transaminase is not
It can be applied only to the fractionation to racemic modification, it can be with catalytic precursor ketone substrate asymmetric syntheses chirality aminated compounds.ω-
Transaminase is wider in the chiral amine compound range of preparation, therefore has more application value.
In protein molecule transformation, currently used method rationality design, nonideal explosives and half design and rational.Three
Whether the main distinction of kind method is whether to fully understand zymoprotein molecular structure and need using bioinformatics software
It is calculated and is predicted.Wherein design and rational has many advantages, such as that experimental cost is low, the simple and convenient and time is short.
Although ω-transaminase has huge application and researching value, ω-transaminase for being filtered out from wild mushroom
Can not specific catalytic sitafloxacin five-membered ring key intermediate, be allowed to can not further by the ω-transaminase be applied to industry
In production, exploitation and utilization are greatly reduced.
Summary of the invention
To solve the above-mentioned problems, by ω-transaminase from Bacillus pumilus W3, (one kind comes from the present invention
ω-transaminase of bacillus pumilus and the application .201811219769.7 in biological amination) carry out heterogenous expression and fixed point
Mutation transformation, enables improved ω-transaminase specific catalytic sitafloxacin five-membered ring key intermediate, turns ammonia to ω-
The industrial applications of enzyme and popularization have far-reaching technological guidance's meaning.
ω of the invention-transaminase mutant, can be five yuan of specific catalytic sitafloxacin compared with parent ω-transaminase
Ring key intermediate.The parental gene and bacillus pumilus (Bacillus pumilus W3) ω-aminotransferase gene
(Sequence ID:MH196528) unanimously, the plasmid template as mutation is to carry natural ω-transaminase coding base
The carrier ota3/pCold II (application number: CN201811219769.7) of cause.
The first purpose of the invention is to provide one kind to be capable of specific catalytic sitafloxacin five-membered ring key intermediate
ω-transaminase mutant, the amino acid sequence of the mutant include: on the basis of the amino acid sequence of SEQ ID NO:1
The tyrosine of the 32nd position is mutated into tryptophan simultaneously, the tyrosine of the 159th position is mutated into phenylalanine, the 215th position
Isoleucine mutation be mutated into amino acid sequence obtained from alanine at the threonine of methionine and the 252nd position, order
Entitled Y32W/Y159F/I215M/T252A.
In one embodiment, the ω-transaminase mutant amino acid sequence, as shown in SEQ ID NO:5
Sequence.
In one embodiment, the ω-transaminase mutant nucleotide sequence, including shown in SEQ ID NO:2
Sequence.
Second object of the present invention is a kind of method for preparing the mutant, is included the following steps:
(1) rite-directed mutagenesis the primer is designed, is mutated simultaneously using carrying ω-transaminase encoding gene carrier as template
Construct the plasmid vector of Y32W/Y159F/I215M/T252A mutant；
(2) the correct recombinant plasmid transformed e. coli bl21 (DE3) of sequence is obtained into recombinant bacterium, recombinant bacterium is fermented and is trained
It supports, obtained fermented supernatant fluid contains ω-transaminase mutant.
In one embodiment, the fermentation is by recombinant bacterium in 37 DEG C of cultures to OD600=0.6, then it is cooled to 15
DEG C and the IPTG of final concentration 0.4mM be added induced, culture for 24 hours when centrifugation obtain upper clear enzyme solution.
In one embodiment, the preparation method is still further comprised using AKTA protein purification instrument and HisTrap
The nickel column of FF crude 1ml purifies ω-transaminase in fermented supernatant fluid.
Third object of the present invention is to provide a kind of recombinant plasmid vectors of amino acid sequence containing the mutant.
In one embodiment, the plasmid vector is appointing in pET series, pGEX series, pCold series or pUB
It anticipates one kind.
The genetic engineering bacterium of the gene for encoding the mutant and the expression mutant is also claimed in the present invention.
The claimed mutant of the present invention, coding state the gene work of the gene of mutant, the expression mutant
Journey bacterium is in food, chemical industry or the application for catalyzing and synthesizing relevant chiral amine in terms of preparing drug, especially in preparation Xi Tasha
Application in star drug.
In one embodiment, the application, including catalytic amino are transferred to amino acceptor by amino group donor compound
Compound.
The application, including the property of can choose catalysis and can chirality synthesis of chiral amine, such as (S) -5-benzyl-5-
Azaspiro [2.4] heptan-7-amine and other unnatural amino acids.
Beneficial effects of the present invention:
ω of the invention-transaminase mutant is based on from R type ω-transaminase of Bacillus pumilus
It is mutated, ω-transaminase mutant Y32W/Y159F/I215M/T252A of building has specific catalytic sitafloxacin
The performance of five-membered ring key intermediate.Enzyme kinetic analysis shows, mutant Y32W/Y159F/I215M/T252A of the invention
KmValue is 4.91 ± 0.38mM；Catalytic efficiency Kcat/KmFor 0.49min-1mM-1.It is catalyzed (S) -5-benzyl-5-azaspiro
[2.4] when heptan-7-amine generates 5-benzyl-5-azaspiro [2.4] heptan-7-one, mutant of the present invention
5-benzyl-5-azaspiro [2.4] heptan-7-one maximum conversion rate is 77.14%.And ω-transaminase parent can not
It is catalyzed sitafloxacin five-membered ring key intermediate (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine.Cause
This, ω of the invention-transaminase mutant is more suitable for ω-transaminase in catalysis (S) -5-benzyl-5-azaspiro than parent
[2.4] application during the Chiral Amines such as heptan-7-amine.
Detailed description of the invention
Fig. 1: natural ω-transaminase three-dimensional simulation structure；
Fig. 2: the chemical structure of sitafloxacin five-membered ring key intermediate；
Fig. 3: natural ω-transaminase and the pure enzyme PAGE gel electrophoresis of mutant；Wherein, swimming lane 1 represents protein molecular
Amount standard, swimming lane 2 are mutant Y32W/Y159F/I215M/T252A, and swimming lane 3 is natural ω-transaminase.
Specific embodiment
The preparation and building of embodiment 1: ω-transaminase directed mutants
From a kind of directed mutants Y32W/Y159F/I215M/ of ω-transaminase of Bacillus pumilus W3
T252A:
In the present invention, with the highest thermophilic archaea transaminase crystal structure of similarity (PDB ID:
It is 5E25) template, Bacillus pumilus W3 ω-transaminase (ω-is constructed by Swiss-Model line server
BPAT three-dimensional simulation structure (Fig. 1)).It is compared and is found by amino acid primary sequences, thermophilic archaea turns ammonia
Similarity reaches 51.21% between the two by enzyme and ω-BPAT, meets the parameter of homologous modeling, it can be considered that ω-BPAT has
The similar three-dimensional structure of thermophilic archaea transaminase.According to software analysis prediction as a result, being mediated using PCR
Directed mutagenesis method construct mutant Y32W/Y159F/I215M/T252A.
The preparation method of directed mutants, according to Bacillus pumilus W3 ω-transaminase sequence (amino acid sequence
Column are as shown in SEQ ID NO:1), the primer of introducing rite-directed mutagenesis is separately designed and synthesizes, to ω-transaminase Y32, Y159,
The position I215 and T252 carries out rite-directed mutagenesis simultaneously, measures DNA encoding sequence, respectively sequencing confirmation ω-transaminase mutant
Whether encoding gene is correct；Mutant gene is connected to expression vector appropriate (pET series, pGEX series, pCold series
Or any one in pUB) in and import in Escherichia coli and expressed, obtain corresponding ω-transaminase directed mutants.
The PCR amplification of directed mutants encoding gene: round pcr is utilized, is template with expression vector ota3/pCold II.
Introduce the mutant primer of Y32W/Y159F/I215M/T252A rite-directed mutagenesis are as follows:
BPTA-F4:5 '-AAAATCTCTTAATTTTCTGAACAACATCCTTGTTCGC-3 ' (SEQ ID NO:3)
BPTA-R4:5 '-GTTGTTCAGAAAATTAAGAGATTTTACTTTTGGCGA-3 ' (SEQ ID NO:4)
BPTA-F5:5 '-TTTCTTACCGGTGCGGCTGCTGAGGTCATCGCAGTT-3 ' (SEQ ID NO:6)
BPTA-R5:5 '-CCTCAGCAGCCGCACCGGTAAGAAAAACTTCCTCTG-3 ' (SEQ ID NO:7)
BPTA-F6:5 '-CATGGGTTCTTATGGGGCGATGGGGTCTTCGAAGGC-3 ' (SEQ ID NO:8)
BPTA-R6:5 '-CCCCATCGCCCCATAAGAACCCATGGTCGTATACAG-3 ' (SEQ ID NO:9)
BPTA-F7:5 '-CATTAGAGGGTATGACCCGCAACGCAATTATGGAGA-3 ' (SEQ ID NO:10)
BPTA-R7:5 '-GCGTTGCGGGTCATACCCTCTAATGCGCCAATATAA-3 ' (SEQ ID NO:11)
PCR amplification program setting are as follows: firstly, 95 DEG C of initial denaturation 3min；It is recycled subsequently into 25: 95 DEG C of denaturation 20s, 60
DEG C annealing 20s, 72 DEG C of extension 1min 40s；Last 72 DEG C of extensions 10min, 4 DEG C of heat preservations.PCR product 1% Ago-Gel electricity
Swimming is detected.
After purification, DPn I is added, 37 DEG C, water-bath 1h, then template of degrading assembles mutant fragments, later in PCR product
Transformed E .coli JM109, picking positive colony, LB liquid medium culture 8-10h protect glycerol tube, send to sequencing.Sequencing is just
True mutant (amino acid sequence as shown in SEQ ID NO:5, nucleotide sequence as shown in SEQ ID NO:2), from glycerol tube
It is seeded to LB culture medium, is incubated overnight, plasmid is extracted, it is thin that plasmid is converted expression host e. coli BL21 (DE3) competence
Born of the same parents obtain that mutant Y32W/Y159F/I215M/T252A recombinant bacterial strain can be expressed.
Embodiment 2: the expression and purification of natural ω-transaminase and its directed mutants
The positive monoclonal that picking is transferred to expressive host e. coli bl21 (DE3) (contains 30 μ g/mL in LB liquid medium
Ampicillin) 8~10h of growth, seed fermentation liquid is connected to LB liquid medium (containing 30 μ g/mL ammonia benzyls blueness by 5% inoculum concentration
Mycin)；Escherichia coli are in 37 DEG C of shaking table culture 2h, until OD600=0.6 or so, mutant Y32W/Y159F/I215M/T252A weight
The IPTG that 0.05mM final concentration is added in group bacterial strain induces extracellular expression, and after 15 DEG C of shaking tables continue cultivation and fermentation for 24 hours, will ferment
Liquid removes thallus in 4 DEG C, 8000g centrifugation 10min, collects centrifugation fermented supernatant fluid.In the case where magnetic stir bar stirs at low speed, to mutation
60% (NH is slowly added in body fermented supernatant fluid4)2SO4, place for 4 DEG C and saltout overnight.4 DEG C, 10000g centrifugation 20min, it is heavy to collect
It forms sediment.After redissolving precipitating with 5.3 citrate-phosphate disodium hydrogen buffer of 50mmol/L pH, in 5.3 lemon of 50mmol/L pH
During which dialysed overnight in acid-disodium hydrogen phosphate buffer replaces 2-3 elution buffer, be made after being filtered by 0.22 μm of film
Loading sample.The purifying of recombinant protein is carried out using AKTA avant protein purification instrument, the control of whole process of purification temperature is 4
℃.Cation exchange chromatography step: (1) it balances: with the 5.3 citrate-phosphate disodium hydrogen of 50mmol/L pH of 5 times of volumes
Buffer balances strong cation exchange chromatography column；(2) loading: the sample pre-processed is with the flow velocity loading of 1mL/min；(3)
Elution: including eluting unadsorbed substance, foreign protein and destination protein, flow velocity 1.0mL/min, eluent is to contain 1M NaCl's
The citrate-phosphate disodium hydrogen buffer of 50mmol/L pH 5.3, carries out linear elution, and Detection wavelength 280nm is received in batches
Collect the eluent of the enzyme activity containing sucrose isomerase；Only there is a destination protein eluting peak, subsequent survey enzyme activity and SDS- in elution process
The discovery of PAGE protein electrophoresis, either wild type or mutant, the enzyme solution that summit is collected are most pure part.Such as Fig. 3 institute
Show.
Embodiment 3: enzyme activity analysis method
ω-method the reference of transaminase enzyme activity determination Gao, S. (Gao, S., Su, Y., Zhao, L., Li, G., Zheng, G.,
2017.Characterization of a(R)-selective amine transaminase from Fusarium
oxysporum.Process.Biochem.63,130-136.)。
Appropriate thallus supernatant (or purifying dilution enzyme solution) is taken, 500 μ L sodium dihydrogen phosphates/disodium hydrogen phosphate buffering is added
Liquid (100mM, pH7.0) contains 20mM (R)-α-phenethylamine (or (S)-α-in the buffer
Phenethylamine), 20mM Sodium Pyruvate, 5 '-phosphate of 0.1mM pyridoxal (PLP) are mixed, 45 DEG C of difference
15min is reacted, the ethyl acetate that isodose is then added terminates reaction.Absorbance of the measurement reaction front and back solution at 254nm.
Under the above conditions, it is catalyzed enzyme amount required for 1 μm of ol correlation ketone in 1 minute, is defined as an enzyme-activity unit
(U/ml).Pass through △ A254Calculate ω-transaminase enzyme activity.U/ml=(△ A/min) * (V*/rvb)；△ A/min- absorbance becomes
Change；V- reaction system volume (ml)；；R- molar extinction coefficient (cm2/umol)；V- sample size (ml)；B- cuvette light path
(cm), above-mentioned dosage can be scaling up or reduce.
After measured, native enzyme is 1.1760U/mL to the thick enzyme activity of substrate (R)-α-phenethylamine, and to (S)-
α-phenethylamine does not have enzyme activity；Recombination mutation ω-transaminase of the invention is then to (R)-α-phenethylamine (or
(S)-α-phenethylamine) all without activity.
Embodiment 4: mutant is in sitafloxacin five-membered ring key intermediate (S) -5-benzyl-5-azaspiro [2.4]
Application in heptan-7-amine production
ω-transaminase can be divided into R- ω-transaminase and S- ω-transaminase, and different types of ω-transaminase can be catalyzed
Substrate type it is different, therefore can produce the product with different optical characteristics.The present embodiment is with (S) -5-benzyl-5-
Azaspiro [2.4] heptan-7-amine (or (R) -5-benzyl-5-azaspiro [2.4] heptan-7-amine) is ammonia
Base donor, Sodium Pyruvate are amino acceptor, detect recombinase obtained and are mutated recombinase to its catalytic capability, to sentence
Whether the enzyme that breaks can be catalyzed (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine with specific efficient, with determination
Its application in sitafloxacin five-membered ring key intermediate commercial synthesis.
Chiral synthesis catalytic experiment: appropriate purifying dilution enzyme solution is taken, it is slow that 500 μ L sodium dihydrogen phosphates/disodium hydrogen phosphate is added
Fliud flushing (100mM, pH7.0) contains 20mM (S) -5-benzyl-5-azaspiro [2.4] heptan-7- in the buffer
Amine (or (R) -5-benzyl-5-azaspiro [2.4] heptan-7-amine), 20mM Sodium Pyruvate, 0.1mM
5 '-phosphate of pyridoxal (PLP) is mixed, and 45 DEG C are reacted 15min respectively, and the ethyl acetate that isodose is then added is whole
Only react.12,000 × g is centrifuged 1min, takes upper organic phase, and 0.22 μm of membrane filtration carries out efficient liquid phase (HPLC) detection,
Detection product is 5-benzyl-5-azaspiro [2.4] heptan-7-one.
Testing conditions:
Pillar: Agilent C18column (250*4.6mm, Agilent, USA)；Mobile phase: acetonitrile/water (95/5, v/
v)；Flow velocity: 1mL/min；Detection wavelength: 220nm.
Table 1
Control sample: using (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine as substrate, in above-mentioned reaction
Under the conditions of detect natural ω-transaminase to its catalytic capability.
Test sample: using (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine as substrate, in above-mentioned reaction
Under the conditions of detection ω-transaminase Y32W/Y159F/I215M/T252A mutant to its catalytic capability.
Statistics indicate that the recombinase (is to urge with ω-transaminase Y32W/Y159F/I215M/T252A mutant to experimental group
Agent) catalytic activity be better than control group (using natural ω-transaminase as catalyst).It is above-mentioned statistics indicate that recombination ω-turns ammonia
Enzyme Y32W/Y159F/I215M/T252A mutant has the function of efficient selective synthesis sitafloxacin five-membered ring key intermediate
Can, there is larger application potential (being shown in Table 2).
Table 2
Enzyme activity (U/mg): it is catalyzed enzyme amount required for 1 μm of ol correlation ketone in 1 minute, is defined as an enzyme-activity unit (U/
mg)。
The Determination of Kinetic Parameters of embodiment 5: ω-transaminase mutant
The method reference of ω-transaminase Determination of Kinetic Parameters Gao, S. (Gao, S., Su, Y., Zhao, L., Li, G.,
Zheng,G.,2017.Characterization of a(R)-selective amine transaminase from
Fusarium oxysporum.Process.Biochem.63,130-136.)。
The present embodiment determines the purifying of embodiment 2 and obtains enzyme mutant Y32W/Y159F/I215M/T252A (amino acid sequence
Arrange as shown in SEQ ID NO:5) kinetic parameter at 45 DEG C.Specific implementation method are as follows: take appropriate thallus supernatant (or
Purifying dilution enzyme solution), 500 μ L sodium dihydrogen phosphates/disodium hydrogen phosphate buffer (100mM, pH7.0) is added, contains in the buffer
Having (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine of various concentration, (specific concentration gradient is referring to above-mentioned text
Offer), 20mM Sodium Pyruvate, 5 '-phosphate of 0.1mM pyridoxal (PLP) is mixed, and 45 DEG C are reacted 15min respectively, so
The ethyl acetate that isodose is added afterwards terminates reaction.The results are shown in Table 3 for dynamics research.
The results show that the K of mutant Y32W/Y159F/I215M/T252AmValue is 4.91mM.In addition, Y32W/Y159F/
The catalytic constant K of I215M/T252AcatFor 2.4min-1.The catalytic efficiency K of mutant Y32W/Y159F/I215M/T252Acat/
KmFor 0.49min-1·mM-1。
As shown in Figure 1, Y32W/Y159F/I215M/T252A is in ω-transaminase catalytic center and isomerizing zone, dash forward
Become the structure expansion that may result in the other parts region of catalytic center and isomerizing zone, bigger substrate is entered
To from catalytic center, consequently, it is possible to the substrate specificity and kinetic parameter to enzyme generate active influence.
3 ω of table-transaminase mutant kinetic parameter
Conversion ratio, which refers to, becomes 5-benzyl-5- for (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine
The transformation efficiency of azaspiro [2.4] heptan-7-one.
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not intended to limit the invention, any to be familiar with this skill
The people of art can do various change and modification, therefore protection model of the invention without departing from the spirit and scope of the present invention
Enclosing subject to the definition of the claims.
SEQUENCE LISTING
<110>Southern Yangtze University
<120>a kind of ω-transaminase mutant that can be catalyzed sitafloxacin five-membered ring intermediate
<160> 11
<170> PatentIn version 3.3
<210> 1
<211> 304
<212> PRT
<213>artificial sequence
<400> 1
Met Glu Asp Gln Lys Glu Gln Trp Ile Phe Leu Asn Asp Glu Leu Val
1 5 10 15
Lys Lys Glu Asp Ala Lys Ile Ser Val Tyr Asp His Gly Phe Leu Tyr
20 25 30
Gly Asp Gly Val Phe Glu Gly Ile Arg Val Tyr Asn Gly Asn Ile Phe
35 40 45
Arg Met Lys Glu His Leu Asp Arg Leu Tyr Asp Ser Ala Arg Ser Ile
50 55 60
Met Leu Asn Ile Pro Tyr Ser Leu Glu Glu Leu Thr Glu Lys Met Ile
65 70 75 80
His Thr Val Glu Arg Asn Gly Leu Lys Asp Ala Tyr Ile Arg Leu Val
85 90 95
Val Ser Arg Gly Ala Gly Asp Leu Gly Leu Asp Pro Asn Asn Cys Gly
100 105 110
Arg Ala Asn Thr Val Ile Ile Val Glu Pro Leu Ala Ile Phe Pro Lys
115 120 125
His Leu Tyr Glu Thr Gly Ile Asp Ile Val Thr Val Pro Thr Arg Arg
130 135 140
Asn Arg Pro Asp Val Leu Ser Pro Lys Val Lys Ser Leu Asn Tyr Leu
145 150 155 160
Asn Asn Ile Leu Val Arg Ile Glu Ala His Met Ala Gly Val Ser Glu
165 170 175
Ala Leu Met Leu Asn Asp Gln Gly Tyr Val Ala Glu Gly Ser Ala Asp
180 185 190
Asn Val Phe Ile Tyr Lys Lys Gly Lys Leu Tyr Thr Pro Pro Gly Tyr
195 200 205
Ile Gly Ala Leu Glu Gly Ile Thr Arg Asn Ala Ile Met Glu Ile Ala
210 215 220
Glu Asp Leu Gly Tyr Glu Val Lys Glu Glu Pro Phe Thr Arg His Asp
225 230 235 240
Val Tyr Thr Ala Glu Glu Val Phe Leu Thr Gly Thr Ala Ala Glu Val
245 250 255
Ile Ala Val Val Lys Val Asp Gly Arg Met Ile Gly Glu Gly Lys Pro
260 265 270
Gly Phe His Thr Asn Lys Leu Leu Glu Gln Phe Arg Lys Arg Val Val
275 280 285
Glu Glu Gly Glu Lys Val Val Phe Thr Asp Glu Asn Ile His Ala Ser
290 295 300
<210> 2
<211> 915
<212> DNA
<213>artificial sequence
<400> 2
atggaggatc agaaggaaca gtggatcttt ctgaacgatg agctggtgaa gaaggaagac 60
gcaaaaatct ctgtatacga ccatgggttc ttatggggcg atggggtctt cgaaggcatt 120
cgtgtctaca acggcaatat cttccgtatg aaagaacatt tggaccgcct ttacgatagc 180
gcacgtagta ttatgttgaa tatcccgtat tcacttgaag agctgacaga aaagatgatt 240
cacacagttg agcgtaacgg tttgaaggat gcttacatcc gcttggtcgt gtctcgcgga 300
gcgggcgact tgggattaga cccgaacaat tgtggtcgcg ccaatactgt tatcattgtt 360
gaacctctgg caattttccc gaaacatttg tacgagaccg gcatcgacat tgtaacggtt 420
cccacccgcc gtaatcgtcc cgatgtcctt tcgccaaaag taaaatctct taattttctg 480
aacaacatcc ttgttcgcat tgaggcccac atggcaggtg taagtgaagc gttaatgctt 540
aatgatcaag gatatgtagc cgaagggtcg gctgataatg tttttatcta taaaaaaggt 600
aaactgtaca ctccgccagg ttatattggc gcattagagg gtatgacccg caacgcaatt 660
atggagattg cggaagatct tgggtacgag gtcaaggaag agcctttcac gcgccatgac 720
gtctatacag cagaggaagt ttttcttacc ggtgcggctg ctgaggtcat cgcagttgta 780
aaggttgacg gacgcatgat tggcgaagga aagccggggt tccacactaa caaattactt 840
gaacaattcc gcaaacgcgt agtggaggag ggagagaagg ttgtctttac ggatgaaaat 900
atccatgcgt cgtaa 915
<210> 3
<211> 37
<212> DNA
<213>artificial sequence
<400> 3
aaaatctctt aattttctga acaacatcct tgttcgc 37
<210> 4
<211> 36
<212> DNA
<213>artificial sequence
<400> 4
gttgttcaga aaattaagag attttacttt tggcga 36
<210> 5
<211> 304
<212> PRT
<213>artificial sequence
<400> 5
Met Glu Asp Gln Lys Glu Gln Trp Ile Phe Leu Asn Asp Glu Leu Val
1 5 10 15
Lys Lys Glu Asp Ala Lys Ile Ser Val Tyr Asp His Gly Phe Leu Trp
20 25 30
Gly Asp Gly Val Phe Glu Gly Ile Arg Val Tyr Asn Gly Asn Ile Phe
35 40 45
Arg Met Lys Glu His Leu Asp Arg Leu Tyr Asp Ser Ala Arg Ser Ile
50 55 60
Met Leu Asn Ile Pro Tyr Ser Leu Glu Glu Leu Thr Glu Lys Met Ile
65 70 75 80
His Thr Val Glu Arg Asn Gly Leu Lys Asp Ala Tyr Ile Arg Leu Val
85 90 95
Val Ser Arg Gly Ala Gly Asp Leu Gly Leu Asp Pro Asn Asn Cys Gly
100 105 110
Arg Ala Asn Thr Val Ile Ile Val Glu Pro Leu Ala Ile Phe Pro Lys
115 120 125
His Leu Tyr Glu Thr Gly Ile Asp Ile Val Thr Val Pro Thr Arg Arg
130 135 140
Asn Arg Pro Asp Val Leu Ser Pro Lys Val Lys Ser Leu Asn Phe Leu
145 150 155 160
Asn Asn Ile Leu Val Arg Ile Glu Ala His Met Ala Gly Val Ser Glu
165 170 175
Ala Leu Met Leu Asn Asp Gln Gly Tyr Val Ala Glu Gly Ser Ala Asp
180 185 190
Asn Val Phe Ile Tyr Lys Lys Gly Lys Leu Tyr Thr Pro Pro Gly Tyr
195 200 205
Ile Gly Ala Leu Glu Gly Met Thr Arg Asn Ala Ile Met Glu Ile Ala
210 215 220
Glu Asp Leu Gly Tyr Glu Val Lys Glu Glu Pro Phe Thr Arg His Asp
225 230 235 240
Val Tyr Thr Ala Glu Glu Val Phe Leu Thr Gly Ala Ala Ala Glu Val
245 250 255
Ile Ala Val Val Lys Val Asp Gly Arg Met Ile Gly Glu Gly Lys Pro
260 265 270
Gly Phe His Thr Asn Lys Leu Leu Glu Gln Phe Arg Lys Arg Val Val
275 280 285
Glu Glu Gly Glu Lys Val Val Phe Thr Asp Glu Asn Ile His Ala Ser
290 295 300
<210> 6
<211> 36
<212> DNA
<213>artificial sequence
<400> 6
tttcttaccg gtgcggctgc tgaggtcatc gcagtt 36
<210> 7
<211> 36
<212> DNA
<213>artificial sequence
<400> 7
cctcagcagc cgcaccggta agaaaaactt cctctg 36
<210> 8
<211> 36
<212> DNA
<213>artificial sequence
<400> 8
catgggttct tatggggcga tggggtcttc gaaggc 36
<210> 9
<211> 36
<212> DNA
<213>artificial sequence
<400> 9
ccccatcgcc ccataagaac ccatggtcgt atacag 36
<210> 10
<211> 36
<212> DNA
<213>artificial sequence
<400> 10
cattagaggg tatgacccgc aacgcaatta tggaga 36
<210> 11
<211> 36
<212> DNA
<213>artificial sequence
<400> 11
gcgttgcggg tcataccctc taatgcgcca atataa 36
Claims (10)
1. a kind of ω-transaminase mutant, which is characterized in that the amino acid sequence of the mutant includes: in SEQ ID NO:1
Amino acid sequence on the basis of, while by the tyrosine of the 32nd position be mutated into tryptophan, the 159th position tyrosine be mutated
It is mutated into alanine at the threonine of methionine, the 252nd position at the isoleucine mutation of phenylalanine, the 215th position, and
Obtained amino acid sequence.
2. ω according to claim 1-transaminase mutant, which is characterized in that the ω-transaminase mutant amino
Acid sequence is sequence shown in SEQ ID NO:5.
3. ω according to claim 1-transaminase mutant, which is characterized in that the ω-transaminase mutant nucleosides
Acid sequence, including sequence shown in SEQ ID NO:2.
4. a kind of recombinant plasmid vector of the amino acid sequence containing mutant described in claim 1.
5. recombinant plasmid vector according to claim 4, which is characterized in that the recombinant plasmid vector be pET series,
Building obtains on the basis of any one plasmid vector in pGEX series, pCold series or pUB.
6. encoding the gene of mutant described in claim 1.
7. expressing the genetic engineering bacterium of mutant described in claim 1.
8. the gene of mutant described in any mutant of claim 1-3, coding claim 1, expression claim 1 institute
State the application of the genetic engineering bacterium of mutant.
9. application according to claim 8, which is characterized in that the application includes for food, chemical industry or preparing medicine
Object；Especially preparing the application in sitafloxacin drug.
10. application according to claim 8, which is characterized in that the application, including catalytic amino is by amino group donor chemical combination
Object is transferred to amino acceptor compound；Optionally, the application includes preparation Chiral Amine or unnatural amino acid；Optionally, institute
It states using including catalysis (S) -5-benzyl-5-azaspiro [2.4] heptan-7-amine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811449183.XA CN109486783B (en) | 2018-11-30 | 2018-11-30 | Omega-transaminase mutant capable of catalyzing sitafloxacin five-membered ring intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811449183.XA CN109486783B (en) | 2018-11-30 | 2018-11-30 | Omega-transaminase mutant capable of catalyzing sitafloxacin five-membered ring intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109486783A true CN109486783A (en) | 2019-03-19 |
| CN109486783B CN109486783B (en) | 2020-06-09 |
Family
ID=65698847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811449183.XA Active CN109486783B (en) | 2018-11-30 | 2018-11-30 | Omega-transaminase mutant capable of catalyzing sitafloxacin five-membered ring intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109486783B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014060571A1 (en) * | 2012-10-18 | 2014-04-24 | Sandoz Ag | A process for preparing indoline derivatives |
| CN104894148A (en) * | 2015-04-13 | 2015-09-09 | 浙江科技学院 | Omega-aminotransferase mutant gene and application thereof |
| CN105441404A (en) * | 2015-12-08 | 2016-03-30 | 浙江科技学院 | Omega-transaminase mutant and encoding gene and preparation method thereof |
| CN105950581A (en) * | 2016-06-21 | 2016-09-21 | 浙江科技学院 | Disulfide-bond-introduced omega-aminotransferase mutant and application thereof |
| CN107058256A (en) * | 2017-05-04 | 2017-08-18 | 浙江科技学院 | ω transaminase mutant and its preparation method and application |
| CN107384887A (en) * | 2017-07-05 | 2017-11-24 | 浙江工业大学 | A kind of aminopherase, mutant and its application for preparing sitagliptin |
| CN108048419A (en) * | 2017-11-15 | 2018-05-18 | 凯莱英生命科学技术(天津)有限公司 | Transaminase mutant and its application |
-
2018
- 2018-11-30 CN CN201811449183.XA patent/CN109486783B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014060571A1 (en) * | 2012-10-18 | 2014-04-24 | Sandoz Ag | A process for preparing indoline derivatives |
| CN104894148A (en) * | 2015-04-13 | 2015-09-09 | 浙江科技学院 | Omega-aminotransferase mutant gene and application thereof |
| CN105441404A (en) * | 2015-12-08 | 2016-03-30 | 浙江科技学院 | Omega-transaminase mutant and encoding gene and preparation method thereof |
| CN105950581A (en) * | 2016-06-21 | 2016-09-21 | 浙江科技学院 | Disulfide-bond-introduced omega-aminotransferase mutant and application thereof |
| CN107058256A (en) * | 2017-05-04 | 2017-08-18 | 浙江科技学院 | ω transaminase mutant and its preparation method and application |
| CN107384887A (en) * | 2017-07-05 | 2017-11-24 | 浙江工业大学 | A kind of aminopherase, mutant and its application for preparing sitagliptin |
| CN108048419A (en) * | 2017-11-15 | 2018-05-18 | 凯莱英生命科学技术(天津)有限公司 | Transaminase mutant and its application |
Non-Patent Citations (2)
| Title |
|---|
| GOMM和O"REILLY: "Transaminases for chiral amine synthesis", 《CURRENT OPINION IN CHEMICAL BIOLOGY》 * |
| 高新星: "w-转氨酶分子改造研究进展", 《生物工程学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109486783B (en) | 2020-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10865404B1 (en) | Aspartase mutant, recombinant expression vector and recombinant bacterium containing aspartase mutant, and use thereof | |
| CN108467860B (en) | Method for high yield of gamma-aminobutyric acid | |
| CN113151198B (en) | Gamma-glutamine synthetase mutant, coding gene, amino acid sequence and application thereof | |
| CN112795582B (en) | Enzyme gene suitable for efficiently synthesizing NAD derivative in microorganism | |
| CN113151199B (en) | Gamma-glutamine synthetase mutant with thermal stability, coding gene, amino acid sequence and application thereof | |
| CN108070581B (en) | L-aspartate beta-decarboxylase mutant with improved enzyme activity and application thereof | |
| CN111411094B (en) | (R) -omega-transaminase mutant and application thereof | |
| CN109609477B (en) | Alpha-transaminase mutant and application thereof in asymmetric synthesis of L-glufosinate-ammonium | |
| US10612054B2 (en) | Single-cell factory for efficiently synthesizing α-aminobutyric acid and construction and application thereof | |
| CN109370998A (en) | A kind of ω-transaminase mutant I215F that catalytic efficiency improves | |
| CN111534494B (en) | (R) -omega-transaminase mutant and application thereof in preparation of sitagliptin intermediate | |
| CN109609478A (en) | α-transaminase and mutant and the application in asymmetric syntheses L-glufosinate-ammonium | |
| CN109777788B (en) | Leucine dehydrogenase mutant and application thereof | |
| CN115976129A (en) | Method for preparing ergothioneine | |
| CN108998462B (en) | Escherichia coli expression system of manganese ion-containing recombinant protein and application method thereof | |
| CN109486780A (en) | A kind of ω-transaminase mutant that catalytic efficiency improves | |
| CN112522228B (en) | R-aminotransferase from pseudomonas ammoxidation and synthesis method thereof | |
| CN113583997A (en) | Phosphatase mutant and application thereof in catalyzing maltodextrin to prepare mannose | |
| CN109486783A (en) | A kind of ω being catalyzed sitafloxacin five-membered ring intermediate-transaminase mutant | |
| CN109486784A (en) | A kind of ω that can be catalyzed sitafloxacin five-membered ring key intermediate-transaminase mutant | |
| CN109468297A (en) | A kind of ω that can be catalyzed sitafloxacin five-membered ring intermediate-transaminase mutant | |
| CN109456952A (en) | A kind of ω being catalyzed sitafloxacin five-membered ring key intermediate-transaminase mutant | |
| CN110951706A (en) | Recombinant R-omega-transaminase, mutant and application in asymmetric synthesis of sitagliptin | |
| WO2023035584A1 (en) | Construction and application of yeast engineering bacteria for fermentative production of heparin | |
| CN103966185A (en) | Double-enzyme system for efficiently synthesizing S-adenosylhomocysteine and application method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |